ChemGenex says Ceflatonin shows anticancer responses

By Elaine Rigoli

Tampa, Fla., April 4 - ChemGenex Pharmaceuticals Ltd. announced three discoveries at the American Association of Cancer Research annual meeting in Washington D.C., including data that Ceflatonin, currently in phase 2 clinical trials for use in various leukemia indications, can suppress the development of blood vessels, a process known as angiogenesis.

The company also released observations showing that Quinamed, which is in phase 2 clinical trials for use in various solid tumors, has synergistic effects when used with some anti-leukemic agents.

Using a cell-culture model of acute myeloid leukemia, it was shown that Quinamed combined with mitoxantrone resulted in more than additive anticancer responses. This result suggests possible future combination therapies for a range of leukemias, according to a news release.

ChemGenex said its third discovery shows that CXS299 causes cell death when used to treat breast and prostate cancer cell lines that are resistant to cisplatin, a widely used anticancer agent.

CXS299 maintains the ability to activate the tumor suppressor protein p53 in resistant cells, an ability that existing therapeutics lack, the release said.

This discovery confirms that CXS299 has significant potential as a therapeutic agent for patients who have inherent resistance, or who develop resistance to cisplatin, the release said.

ChemGenex is a Melbourne, Australia-based pharmaceutical development company developing therapeutics in the areas of oncology, diabetes, obesity and depression.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.